3 Contract Research and Manufacturing, Fermentation-Based Ingredients and Custom Synthesis Leader Stocks With a Strong Future Roadmap: Sai Life Sciences, Concord Biotech and Divi’s Laboratories
- October 23, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Sai Life Sciences, Concord Biotech and Divi’s Laboratories: ROE of 12.9% to 15.3% and FY22 to FY26 revenue CAGR of 5.1% to 25.7%. Prices as of 22 Oct 2026.
Quick Answer
The three CDMO and fermentation-based pharma stocks to watch are Sai Life Sciences, Concord Biotech and Divi’s Laboratories. Their return on equity ranges from 12.9% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 25.7%. Divi’s Laboratories has the highest return on equity at 15.3%, while Sai Life Sciences has the fastest revenue growth at 25.7% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
CDMO and fermentation-based pharma stocks let investors follow companies that make complex molecules for global pharma. Sai Life Sciences, Concord Biotech and Divi’s Laboratories cover a contract research and manufacturing organisation, fermentation-based active ingredients and a custom synthesis leader.
This list covers three CDMO and fermentation-based pharma stocks with complete current figures: Sai Life Sciences, Concord Biotech and Divi’s Laboratories. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are CDMO and Fermentation-based Pharma Stocks?
CDMO and fermentation-based pharma stocks are listed companies that provide contract research, development and manufacturing or produce fermentation-based and synthetic ingredients. Their earnings depend on client projects, capacity and approvals.
CDMO and Fermentation-based Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Sai Life Sciences | 1,395.9 | 29,679 | 82.0 | 36.0 | 14.1 | 0.12 |
| Concord Biotech | 1,270.7 | 13,421 | 49.2 | 36.0 | 12.9 | 0.00 |
| Divi’s Laboratories | 9,162 | 241,311 | 82.5 | 36.0 | 15.3 | 0.00 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing CDMO and fermentation-based pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do CDMO and Fermentation-based Pharma Stocks Have a Strong Roadmap in India?
CDMO and fermentation-based pharma stocks have a strong roadmap in India because global pharma and biotech companies are outsourcing more work to partners with deep chemistry skills and reliable plants.
- Outsourcing trend. Global drug makers hand more development to specialist partners.
- Niche ingredients. Fermentation-based products have few qualified suppliers.
- Large-scale plants. Proven capacity wins long-term supply deals.
Why Sai Life Sciences Features Among These CDMO and Fermentation-based Pharma Stocks
Among the CDMO and fermentation-based pharma stocks on this list, Sai Life Sciences is a Hyderabad-based contract research, development and manufacturing organisation that works with global pharma and biotech companies from discovery through commercial supply.
The company has a return on equity of 14.1%, a debt to equity ratio of 0.12 and a market capitalisation of Rs 29,679 crore. The stock trades at a P/E of 82.0, above the industry P/E of 36.0.
Revenue rose from Rs 898 crore in FY22 to Rs 2,242 crore in FY26, a compound annual growth rate of 25.7%. Net profit grew from Rs 170 crore in FY25 to Rs 349 crore in FY26, a rise of 105.1%. In the June 2026 quarter, revenue grew 10.2% year on year to Rs 558 crore, while net profit rose 21.2% to Rs 73.3 crore.
Roadmap: The roadmap is built on adding development and manufacturing capacity and moving more projects from discovery into late-stage and commercial supply. Customers tend to stay with a partner across the drug life cycle, which creates a durable order pipeline.
What to watch: Monitor project conversion from development to commercial stages and customer concentration.
Why Concord Biotech Features Among These CDMO and Fermentation-based Pharma Stocks
Among the biopharma contract research shares on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.
Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%.
In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.
Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What to watch: Monitor the pace of new product introductions and the contribution from formulations.
Why Divi’s Laboratories Features Among These CDMO and Fermentation-based Pharma Stocks
Among the three companies on this list, Divi’s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.
In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%.
Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.
Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.
What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.
Sai Life Sciences vs Concord Biotech vs Divi’s Laboratories on Key Financials
The table below sets the three CDMO and fermentation-based pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Sai Life Sciences | 898 | 2,242 | 25.7% | 349 | 15.6% |
| Concord Biotech | 736 | 1,107 | 10.7% | 259 | 23.4% |
| Divi’s Laboratories | 9,074 | 11,067 | 5.1% | 2,568 | 23.2% |
Divi’s Laboratories posts the highest return on equity in this group at 15.3%. Divi’s Laboratories has the largest FY26 revenue at Rs 11,067 crore, and Sai Life Sciences shows the fastest revenue growth with a 25.7% compound annual rate. A useful habit with CDMO and fermentation-based pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Sai Life Sciences | 506 | 558 | 10.2% |
| Concord Biotech | 218 | 270 | 24.2% |
| Divi’s Laboratories | 2,529 | 3,144 | 24.3% |
Key Risks to Check Before Investing in CDMO and Fermentation-based Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these CDMO and fermentation-based pharma stocks, the main points are: Long-term biopharma contract research shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Project timing. Customer programmes can shift between quarters.
- Regulatory checks. Plant inspections need constant readiness.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter CDMO and fermentation-based pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on CDMO and Fermentation-based Pharma Stocks
CDMO and fermentation-based pharma stocks reward investors who follow client projects, capacity and approvals together. Sai Life Sciences, Concord Biotech and Divi’s Laboratories each hold a strong niche. Based on the 22 October 2026 close, Sai Life Sciences trades at Rs 1,395.9, Concord Biotech at Rs 1,270.7 and Divi’s Laboratories at Rs 9,162. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these CDMO and fermentation-based pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track CDMO and fermentation-based pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are CDMO and fermentation-based pharma stocks?
Ans. CDMO and fermentation-based pharma stocks are listed companies that provide contract research, development and manufacturing or produce fermentation-based and synthetic ingredients. Their earnings depend on client projects, capacity and approvals. This list looks at three of them, Sai Life Sciences, Concord Biotech and Divi’s Laboratories, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which CDMO and fermentation-based pharma stocks are covered in this list?
Ans. This list covers Sai Life Sciences, Concord Biotech and Divi’s Laboratories. Based on the 22 October 2026 close, Sai Life Sciences traded at Rs 1,395.9, Concord Biotech at Rs 1,270.7 and Divi’s Laboratories at Rs 9,162. Their return on equity ranges from 12.9% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 25.7%.
Why do CDMO and fermentation-based pharma stocks have a strong future roadmap in India?
Ans. CDMO and fermentation-based pharma stocks have a strong roadmap in India because global pharma and biotech companies are outsourcing more work to partners with deep chemistry skills and reliable plants. The main drivers are as follows. Outsourcing trend. Global drug makers hand more development to specialist partners. Niche ingredients. Fermentation-based products have few qualified suppliers. Large-scale plants. Proven capacity wins long-term supply deals. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Sai Life Sciences performed financially?
Ans. Revenue rose from Rs 898 crore in FY22 to Rs 2,242 crore in FY26, a compound annual growth rate of 25.7%. Net profit grew from Rs 170 crore in FY25 to Rs 349 crore in FY26, a rise of 105.1%. In the June 2026 quarter, revenue grew 10.2% year on year to Rs 558 crore, while net profit rose 21.2% to Rs 73.3 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.12 and a market capitalisation of Rs 29,679 crore. The stock trades at a P/E of 82.0, above the industry P/E of 36.0. Looking ahead, the roadmap is built on adding development and manufacturing capacity and moving more projects from discovery into late-stage and commercial supply. Customers tend to stay with a partner across the drug life cycle, which creates a durable order pipeline.
How has Concord Biotech performed financially?
Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
How has Divi’s Laboratories performed financially?
Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.
What risks should investors check before buying CDMO and fermentation-based pharma stocks?
Ans. Investors should check a few risks before buying CDMO and fermentation-based pharma stocks. Project timing. Customer programmes can shift between quarters. Regulatory checks. Plant inspections need constant readiness. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of CDMO and fermentation-based pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.